BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/27/2026 12:16:58 PM | Browse: 1 | Download: 0
 |
Received |
|
2025-11-18 09:23 |
|
Peer-Review Started |
|
2025-11-18 09:23 |
|
First Decision by Editorial Office Director |
|
2025-12-09 06:54 |
|
Return for Revision |
|
2025-12-09 06:54 |
|
Revised |
|
2025-12-22 13:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-12 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-12 09:45 |
|
Articles in Press |
|
2026-01-12 09:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-28 03:51 |
|
Publish the Manuscript Online |
|
2026-03-27 12:16 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Feng Shi, Hui Xu, Jin-Feng Gao and Jian-Bin Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jian-Bin Wu, MD, Department of Human Resources, Jiangsu Hengrui Medicine Co.,Ltd, No. 1288 Haike Road, Shanghai 200122, China. 18205137866@163.com |
| Key Words |
Real-world evidence; Irinotecan; Apatinib; Postoperative recurrence; Metastatic gastric cancer |
| Core Tip |
This study presents a real-world data analysis of clinical efficacy outcomes associated with irinotecan-apatinib adjuvant therapy among patients with postoperative recurrent/metastatic gastric cancer (RMGC). We included 124 postsurgical RMGC patients treated from April 2021 to April 2024, all of whom received the S-1 (via intravenous infusion) plus oxaliplatin (via oral administration; S-1+oxaliplatin) regimen. The irinotecan-apatinib adjuvant therapy for these patients demonstrated significant clinical advantages in inhibiting inflammation and serum tumor markers while improving quality of life, which could be a better option for these patients. |
| Publish Date |
2026-03-27 12:16 |
| Citation |
Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569 |
| URL |
https://www.wjgnet.com/1948-9366/full/v18/i3/114569.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v18.i3.114569 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
